Plexxikon, Daiichi Sankyo complete potential $935M deal
April 4, 2011
Daiichi Sankyo Co. Ltd. completed its acquisition of Plexxikon Inc., giving shareholders $805 million upfront with the possibility of near-term milestone payments of another $130 million on Plexxikon’s potential melanoma drug.
Plexxikon will retain its name, employees and Berkeley facilities, and it will continue research and development operations as an independent unit of Tokyo-based Daiichi Sankyo.
The deal was announced in late February.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.